Recursion Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Recursion Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- RXRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001601830
Board of directors
-
Blake Borgeson · DirectorSince 2023
-
Christopher Gibson · Director · Chief Executive OfficerSince 2023
-
Dean Y. Li · DirectorSince 2023
-
Najat Khan · DirectorSince 2024
-
R. Martin Chavez · DirectorSince 2023
-
Robert Hershberg · DirectorSince 2023
-
Terry-Ann Burrell · DirectorSince 2023
-
Zachary Bogue · DirectorSince 2023
-
Zavain Dar · DirectorSince 2023
Chief executives
Christopher Gibson
· Chief Executive Officer
Dates unknown
Board connections
3 of this board's directors also sit on 4 other boards.
- via Robert Hershberg
- via R. Martin Chavez
- via Robert Hershberg
- via Terry-Ann Burrell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 27, 2024 | Marriott Tina Officer (President and COO) | Option exercise | +6,000 | $1.06 | $6,360 |
| Jun 27, 2024 | Marriott Tina Officer (President and COO) | Open-market sale | −6,000 | $7.22 | $43,320 |
| Jun 25, 2024 | Blake Borgeson Director | Open-market sale | −11,447 | $9.51 | $108,861 |
| Jun 14, 2024 | Secora Michael Officer (Chief Financial Officer) | Option exercise | +39,375 | $2.22 | $87,413 |
| Jun 14, 2024 | Secora Michael Officer (Chief Financial Officer) | Open-market sale | −15,000 | $9.27 | $139,050 |
| Jun 13, 2024 | Secora Michael Officer (Chief Financial Officer) | Option exercise | +39,375 | $2.22 | $87,413 |
| Jun 13, 2024 | Secora Michael Officer (Chief Financial Officer) | Open-market sale | −15,000 | $9.32 | $139,800 |
| Jun 11, 2024 | Blake Borgeson Director | Open-market sale | −11,447 | $8.45 | $96,727 |
| Jun 6, 2024 | Christopher Gibson Director, Officer (Chief Executive Officer) | Open-market sale | −50,000 | $9.00 | $450,000 |
| Jun 5, 2024 | Christopher Gibson Director, Officer (Chief Executive Officer) | Derivative conversion | +25,000 | — | — |
| Jun 5, 2024 | Christopher Gibson Director, Officer (Chief Executive Officer) | Gift | −25,000 | — | — |
| Jun 5, 2024 | Christopher Gibson Director, Officer (Chief Executive Officer) | Open-market sale | −50,000 | $8.42 | $421,000 |
| Jun 3, 2024 | Terry-Ann Burrell Director | Grant or award | +13,097 | — | — |
| Jun 3, 2024 | Robert Hershberg Director | Grant or award | +13,097 | — | — |
| Jun 3, 2024 | Blake Borgeson Director | Grant or award | +13,097 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.